Programmed-death ligand-1 (PD-L1) status has been used to guide immune checkpoint blockades (ICBs), including atezolizumab and pembrolizumab, in metastatic triple-negative breast cancer (mTNBC) [1,2]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.